116 related articles for article (PubMed ID: 7950502)
1. Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
Gambacciani M; Spinetti A; Piaggesi L; Cappagli B; Taponeco F; Manetti P; Weiss C; Teti GC; La Commare P; Facchini V
Bone Miner; 1994 Jul; 26(1):19-26. PubMed ID: 7950502
[TBL] [Abstract][Full Text] [Related]
2. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
Gambacciani M; Cappagli B; Piaggesi L; Ciaponi M; Genazzani AR
Calcif Tissue Int; 1997; 61 Suppl 1():S15-8. PubMed ID: 9263611
[TBL] [Abstract][Full Text] [Related]
3. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
5. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
6. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
[TBL] [Abstract][Full Text] [Related]
7. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
8. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
de Aloysio D; Gambacciani M; Altieri P; Ciaponi M; Ventura V; Mura M; Genazzani AR; Bottiglioni F
Gynecol Endocrinol; 1997 Aug; 11(4):289-93. PubMed ID: 9272427
[TBL] [Abstract][Full Text] [Related]
9. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
[TBL] [Abstract][Full Text] [Related]
10. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
11. Effect of ipriflavone on bone mass in elderly osteoporotic women.
Passeri M; Biondi M; Costi D; Bufalino L; Castiglione GN; Di Peppe C; Abate G
Bone Miner; 1992 Oct; 19 Suppl 1():S57-62. PubMed ID: 1422322
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
13. Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D.
Sato Y; Kuno H; Kaji M; Saruwatari N; Oizumi K
Am J Phys Med Rehabil; 1999; 78(5):457-63. PubMed ID: 10493456
[TBL] [Abstract][Full Text] [Related]
14. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
[TBL] [Abstract][Full Text] [Related]
15. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
Taga M; Minaguchi H
Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ipriflavone in established osteoporosis and long-term safety.
Agnusdei D; Bufalino L
Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy.
Gambacciani M; Spinetti A; Taponeco F; Ciaponi M; Cima GP; Teti GC; Genazzani AR
Gynecol Endocrinol; 1995 Jun; 9(2):131-5. PubMed ID: 7502689
[TBL] [Abstract][Full Text] [Related]
18. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
Newhall-Perry K; Holloway L; Osburn L; Monroe SE; Heinrichs L; Henzl M; Marcus R
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):824-9. PubMed ID: 7573251
[TBL] [Abstract][Full Text] [Related]
19. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy.
Stroup GB; Hoffman SJ; Vasko-Moser JA; Lechowska BA; Jenkins EL; Dare LC; Gowen M
Bone; 2001 May; 28(5):532-7. PubMed ID: 11344053
[TBL] [Abstract][Full Text] [Related]
20. Effects of ipriflavone on bone remodeling in primary hyperparathyroidism.
Mazzuoli G; Romagnoli E; Carnevale V; Scarda A; Scarnecchia L; Pacitti MT; Rosso R; Minisola S
Bone Miner; 1992 Oct; 19 Suppl 1():S27-33. PubMed ID: 1422317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
